Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-In-Human Phase 1b/2a Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adult Participants With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization

Next Previous
Trial Profile

First-In-Human Phase 1b/2a Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adult Participants With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EG 110A (Primary)
  • Indications Neurogenic bladder
  • Focus Adverse reactions; First in man
  • Sponsors EG 427

Most Recent Events

  • 27 Feb 2025 According to a EG 427 media release, first patient has been successfully dosed and treated in this study. This trial is conducted at four leading US institutions located in California, Michigan, Pennsylvania and Texas. The first patient was treated at Rancho Research Institute of Rancho Los Amigos National Rehabilitation Center in Downey, greater Los Angeles area, by the team of Dr. Evgeniy Kreydin, MD.
  • 20 Feb 2025 According to a Cohesion Technologies media release, the company raises 27 million EUROs series financing to fund this ongoing phase 1b/2a study of EG110A through safety and early efficacy results.
  • 09 Jan 2025 Planned initiation date changed from 1 Dec 2024 to 1 Jan 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top